Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 48, Issue 9, Pages A24-A32Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2006.04.097
Keywords
-
Categories
Ask authors/readers for more resources
Since their discovery in the early 1990s, the members of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors have been recognized as therapeutic targets against dyslipidemia and diabetes. Recent studies also identified anti-inflammatory actions of PPARs in cells constituting the atherosclerotic lesion. Delineation of this activity extended the therapeutic potential of PPAR activators beyond their original design as metabolic controllers. The PPAR family consists of 3 PPAR isoforms: alpha, beta/delta, and gamma, which exert different and sometimes overlapping effects on whole-body physiology in particular on lipid and glucose metabolism. This review summarizes the current knowledge on the role of PPARs in cardiovascular disease, the metabolic syndrome, atherosclerosis, and cardiac function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available